Goldman said in a memo to staff, seen by The NYT, that it would require clients and staff to be fully vaccinated before entering US offices.
Many children attending school are currently ineligible for COVID-19 vaccinations, which has contributed to an increase in pediatric cases.
<img src="https://i.insider.com/610ac935c31de700184a37f8?format=jpeg" alt="Stock photo of doctors analyzing a lung cancer scan." height="1815" width="3630" charset="">
<span class="copyright">BSIP/Universal Images Group via Getty Images</span>
<li>BeyondSpring surged 197% Wednesday after announcing it is seeking FDA approval for its cancer drug.</li>
<li>The company said plinabulin met the primary endpoint of significantly improving the overall survival of patients.</li>
<li>Shares of BeyondSpring surged to their highest price since May 2018.</li>
<li><a href="https://newsletter.businessinsider.com/join/4np/10-things-opening-bell?utm_source=markets&utm_medium=ingestgest"><strong>Sign up here for our daily newsletter, 10 Things Before the Opening Bell</strong></a><strong>.</strong></li>
</ul><p>Shares of BeyondSpring surged 197% on Wednesday after the New York-based biopharmaceutical company announced it is now seeking approval from the US Food and Drug Administration for its cancer-drug trial.</p><p>Shares of the company were trading at their highest level since May 2018. The stock was up 188%, at $27.74 as of 1:32 p.m. ET.</p><p>The company on Wednesday said plinabulin, its lead drug, met the primary endpoint of significantly improving the overall survival of patients during the DUBLIN-3 phase three trial of its lung cancer treatment.</p><p>The study also met secondary endpoints including boosting overall response rate, progression-free survival, and 24-36 months of overall survival rates. </p><p>BeyondSpring also said it plans to seek approval from China's drug regulator.</p><p>Dr. Lan Huang, co-founder, CEO, and chair, <a href="https://www.globenewswire.com/news-release/2021/08/04/2274399/0/en/BeyondSpring-Announces-Positive-Topline-Results-from-its-DUBLIN-3-Registrational-Trial-of-Plinabulin-in-Combination-with-Docetaxel-for-the-Treatment-of-2nd-3rd-Line-Non-Small-Cell-.html">said</a> she will set a pre-non-disclosure agreement meeting with the FDA in 2021 to agree on the contents of their NDA. This, she said, will support a submission in the first half of 2022. </p><p>"The strong results from DUBLIN-3 further validate our conviction that plinabulin, as an immune anti-cancer agent, has the potential to be a cornerstone therapy for many solid tumors," Huang said.</p><p>Plinabulin is a novel, intravenous-infused, patent-protected drug candidate for non-small cell lung cancer.</p><p>The company's stock last week closed at a record-low.</p><div class="read-original">Read the original article on <a href="https://www.businessinsider.com/beyondspring-bysi-stock-price-soars-198-lung-cancer-fda-approval-2021-8">Business Insider</a></div>
The drug can help with chronic weight management in people who are overweight or obese and who have at least one weight-related condition.
"We know that we are delayed from where we thought we would be at this point," Novavax CEO Stanley Erck reportedly said Monday.
Full approval by the FDA means the pharma companies will be able to administer vaccines after the pandemic state of emergency is lifted.
Apart from this, the FDA will give the company access to more frequent meetings and may even grant Immutep "accelerated approval and priority review."
Aveo shares moved higher for a second day after the Food and Drug Administration approved Fotivda to treat certain adults with renal cancer.
KemPharm stock skyrocketed on Wednesday after the FDA approved the company's once-daily treatment for ADHD, Azstarys.
Pfizer’s chief executive sees “no issues” in delivering on its COVID-19 vaccine commitments. The company will be able to deliver `at least’ 2 billion doses globally, CEO Albert Bourla said. Visit Business Insider’s homepage for more stories. Pfizer’s chief executive officer is confident that the company can deliver 2 billion […]
Myovant shares gained as much as 35% on Monday after announcing a partnership with Pfizer to develop and commercialize a relugolix drug for the treatment of prostate cancer patients. Myovant and Pfizer are also awaiting regulatory approval for a relugolix combination drug that could treat patients with uterine fibroids and […]